About Us
Company History
Our Mission
Management Team
Board of Directors
Technology
The Problem
The Solution: Our Microbial Platforms
C1
Dapibus™
Advantages and Opportunities
Pipeline
Human Health
Animal Health
Alternative Proteins
Partners
Investors
Overview
Press Releases
SEC Filings
Financials
Investor Fact Sheet
Analyst Coverage
Corporate Governance
Annual Meeting and Proxy
Stock Information
Earnings Calls
Email Alert Opt-in
Media
Articles
Events
Presentations
Press Releases
Scientific Publications
Video Gallery
Contact Us
Snap Quote
Search
Search
Recent Posts
Dyadic Attends Investor Events in December
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
Dyadic to Present at Industry Events in November
Recent Comments
No comments to show.
